This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1989:7:123-30.

doi: 10.1007/978-3-642-74430-3_13.

Animal pharmacology of raclopride, a selective dopamine D2 antagonist

H Hall¹, S O Ogren, C Köhler, O Magnusson

Affiliations

PMID: 2687851
DOI: 10.1007/978-3-642-74430-3_13

Review

Animal pharmacology of raclopride, a selective dopamine D2 antagonist

H Hall et al. Psychopharmacol Ser. 1989.

. 1989:7:123-30.

doi: 10.1007/978-3-642-74430-3_13.

Authors

H Hall¹, S O Ogren, C Köhler, O Magnusson

Affiliation

¹ Astra Research Centre AB, CNS2 Research and Development, Neuropharmacology, Södertälje, Sweden.

PMID: 2687851
DOI: 10.1007/978-3-642-74430-3_13

No abstract available

PubMed Disclaimer

Similar articles

Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine.
Wadenberg ML, Ahlenius S, Svensson TH. Wadenberg ML, et al. Psychopharmacology (Berl). 1993;110(3):273-9. doi: 10.1007/BF02251281. Psychopharmacology (Berl). 1993. PMID: 7831419
Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
Lublin H, Gerlach J, Mørkeberg F. Lublin H, et al. Psychopharmacology (Berl). 1994 Apr;114(3):495-504. doi: 10.1007/BF02249341. Psychopharmacology (Berl). 1994. PMID: 7855208
The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
Ogren SO, Hall H, Köhler C, Magnusson O, Sjöstrand SE. Ogren SO, et al. Psychopharmacology (Berl). 1986;90(3):287-94. doi: 10.1007/BF00179179. Psychopharmacology (Berl). 1986. PMID: 2947255
Subtypes of dopamine receptors involved in the mechanism of reinforcement.
Nakajima S. Nakajima S. Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):123-8. doi: 10.1016/s0149-7634(89)80020-x. Neurosci Biobehav Rev. 1989. PMID: 2530477 Review.
Raclopride, a new selective ligand for the dopamine-D2 receptors.
Hall H, Köhler C, Gawell L, Farde L, Sedvall G. Hall H, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):559-68. doi: 10.1016/0278-5846(88)90001-2. Prog Neuropsychopharmacol Biol Psychiatry. 1988. PMID: 2975809 Review.

See all similar articles

Cited by

Positron emission tomography in Parkinson's disease: insights into impulsivity.
Stark AJ, Claassen DO. Stark AJ, et al. Int Rev Psychiatry. 2017 Dec;29(6):618-627. doi: 10.1080/09540261.2017.1398139. Epub 2017 Dec 5. Int Rev Psychiatry. 2017. PMID: 29206483 Free PMC article. Review.
Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience.
Beaurain M, Salabert AS, Ribeiro MJ, Arlicot N, Damier P, Le Jeune F, Demonet JF, Payoux P. Beaurain M, et al. Front Med (Lausanne). 2019 Nov 27;6:268. doi: 10.3389/fmed.2019.00268. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31828073 Free PMC article. Review.
Amphetamine-induced dopamine release and impulsivity in Parkinson's disease.
Song AK, Hay KR, Trujillo P, Aumann M, Stark AJ, Yan Y, Kang H, Donahue MJ, Zald DH, Claassen DO. Song AK, et al. Brain. 2022 Oct 21;145(10):3488-3499. doi: 10.1093/brain/awab487. Brain. 2022. PMID: 34951464 Free PMC article. Clinical Trial.
[¹⁸F]fallypride characterization of striatal and extrastriatal D_2/3 receptors in Parkinson's disease.
Stark AJ, Smith CT, Petersen KJ, Trujillo P, van Wouwe NC, Donahue MJ, Kessler RM, Deutch AY, Zald DH, Claassen DO. Stark AJ, et al. Neuroimage Clin. 2018 Feb 10;18:433-442. doi: 10.1016/j.nicl.2018.02.010. eCollection 2018. Neuroimage Clin. 2018. PMID: 29541577 Free PMC article.
Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
Csernansky JG, Newcomer JW, Jackson K, Lombrozo L, Faull KF, Zipursky R, Pfefferbaum A, Faustman WO. Csernansky JG, et al. Psychopharmacology (Berl). 1994 Nov;116(3):291-6. doi: 10.1007/BF02245331. Psychopharmacology (Berl). 1994. PMID: 7534423 Clinical Trial.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions